当前位置:首页 - 行情中心 - 博济医药(300404) - 财务分析 - 利润表

博济医药

(300404)

  

流通市值:25.54亿  总市值:35.40亿
流通股本:2.76亿   总股本:3.82亿

利润表

报告期2024-09-302024-06-302024-03-312023-12-31
公司类型通用通用通用通用
一、营业总收入556,148,773.73341,390,828.56167,424,382.67555,832,418.6
营业收入556,148,773.73341,390,828.56167,424,382.67555,832,418.6
二、营业总成本519,937,507.73318,142,631.73148,329,824.43538,555,406.78
营业成本377,140,098.56230,057,272.34110,777,921.95370,540,784.5
税金及附加5,305,161.393,379,649.521,177,649.794,477,372.29
销售费用38,727,578.7923,456,898.9410,921,840.4841,983,985.87
管理费用53,418,372.2434,003,454.8114,626,113.9567,006,989.61
研发费用44,450,607.5626,820,863.0711,341,330.6654,970,443.28
财务费用895,689.19424,493.05-515,032.4-424,168.77
其中:利息费用2,560,897.371,474,917.07276,764.461,534,742.18
其中:利息收入1,799,050.781,138,380.44854,658.562,134,675.25
加:公允价值变动收益980,609.38554,634.23460,283.73589,892.23
加:投资收益1,481,998.221,378,132.49569,095.832,195,029.28
资产处置收益---931.96
资产减值损失(新)-3,751,485.06-1,315,731.08-981,897.26-6,981,561.39
信用减值损失(新)-11,882,335.6-8,498,561.3-4,089,269.66-11,609,785.37
其他收益8,184,065.054,104,516.321,561,755.6416,167,524.13
营业利润平衡项目0000
四、营业利润31,224,117.9919,471,187.4916,614,526.5217,639,042.66
加:营业外收入45,041.3244,930.7844,187.330,942.76
减:营业外支出105,911.3945,275.7727,021.7540,189.33
利润总额平衡项目0000
五、利润总额31,163,247.9219,470,842.516,631,692.0717,629,796.09
减:所得税费用-14,198,504.19-11,414,448.97-625,013.17-9,562,907.29
六、净利润45,361,752.1130,885,291.4717,256,705.2427,192,703.38
持续经营净利润45,361,752.1130,885,291.4717,256,705.2427,192,703.38
归属于母公司股东的净利润43,277,754.8330,135,149.5716,513,092.1824,339,436.55
少数股东损益2,083,997.28750,141.9743,613.062,853,266.83
(一)基本每股收益0.110.080.040.07
(二)稀释每股收益0.110.080.040.07
八、其他综合收益-369,497.05136,044.61564,543.88667,904.66
归属于母公司股东的其他综合收益-365,486.64132,935.5563,611.48619,707.06
九、综合收益总额44,992,255.0631,021,336.0817,821,249.1227,860,608.04
归属于母公司股东的综合收益总额42,912,268.1930,268,085.0717,076,703.6624,959,143.61
归属于少数股东的综合收益总额2,079,986.87753,251.01744,545.462,901,464.43
公告日期2024-10-262024-08-272024-04-252024-04-25
审计意见(境内)标准无保留意见
TOP↑